EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study

Georgios Vlasakakis, Yolanda Alvarez, Timothy Hart, Yu Liu Ho, Catherine Ellis

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1509 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Georgios Vlasakakis und 4 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, PA, USA. Hauptthemen laut MEDLINE: Heart Rate, Pyrimidines, Benzamides. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A randomized, partially blinded, placebo‐controlled, crossover study in 48 healthy adults assessed the effect of momelotinib on the heart rate‐corrected QT interval (QTc) using the Fridericia formula (QTcF). QTc was evaluated for momelotinib 200 mg (therapeutic dose), momelotinib 800 mg (supratherapeutic dose), moxifloxacin 400 mg (positive control), and placebo. Pharmacokinetic profiles of momelotinib and its active metabolite M21 were evaluated. Momelotinib did not prolong QTcF, as the upper bounds of the 2‐sided 90% confidence intervals (CIs) for the mean difference between doses of momelotinib and placebo were 5 milliseconds at 2, 3, and 4 hours after dosing, demonstrating assay sensitivity. There was no positive relationship between momelotinib plasma concentrations and QTcF. Adverse events (AEs) were more frequent with the supratherapeutic dose of momelotinib, but none were considered severe. There were no deaths, serious AEs, or AEs leading to study discontinuation. Neither therapeutic nor supratherapeutic doses of momelotinib led to clinically significant effects on the QTc interval, supporting a negative finding for QTc prolongation from this thorough QT study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart RatePyrimidinesBenzamidesHumansMaleCross-Over StudiesAdultFemaleYoung AdultElectrocardiographyMiddle AgedHealthy VolunteersLong QT SyndromeMoxifloxacinQuinazolines

Stichwörter der Autor:innen

QT intervalcardiac repolarizationmomelotinibmyelofibrosispharmacokinetics

Substanzen

PyrimidinesBenzamidesHM781-36BMoxifloxacinQuinazolines

Autor:innen und Institutionen

  • GSK, Collegeville, PA, USA.
  • GSK, London, UK.

Zitieren

APA

Vlasakakis, G., Alvarez, Y., Hart, T., Ho, Y. L., & Ellis, C. (2025). Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1509

Vancouver

Vlasakakis G, Alvarez Y, Hart T, Ho YL, Ellis C. Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1509

BibTeX
@article{Vlasakakis2025,
  author = {Vlasakakis, Georgios and Alvarez, Yolanda and Hart, Timothy and Ho, Yu Liu and Ellis, Catherine},
  title = {Evaluation of the Effect of Momelotinib on Cardiac Repolarization: A Thorough QT Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1509}
}
Kostenlos starten →